G01N 2800/2842
Pain
Official title: Pain, e.g. neuropathic pain, psychogenic pain
G01N2800/2842 (Pain) appears on 83 US grants and 192 published applications in this corpus.
Search patents in G01N- Granted patents
- 83
- Published applications
- 192
- Assignees
- 107
- Inventors
- 335
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 10 |
| 2006 | 1 | 12 |
| 2007 | 0 | 6 |
| 2008 | 1 | 5 |
| 2009 | 3 | 7 |
| 2010 | 3 | 7 |
| 2011 | 3 | 16 |
| 2012 | 5 | 5 |
| 2013 | 3 | 14 |
| 2014 | 4 | 10 |
| 2015 | 7 | 10 |
| 2016 | 2 | 13 |
| 2017 | 7 | 16 |
| 2018 | 11 | 8 |
| 2019 | 4 | 12 |
| 2020 | 4 | 8 |
| 2021 | 3 | 9 |
| 2022 | 2 | 3 |
| 2023 | 4 | 3 |
| 2024 | 4 | 6 |
| 2025 | 2 | 4 |
| 2026 | 3 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Diagnostic methods for neural disorders15 Sep 2026US 12,736,528 B2Quiver Holdings Inc.
- Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy23 Jun 2026US 12,663,425 B2The Trustees of Columbia University in the City of New York
- Method for diagnosing and treating fibromyalgia24 Feb 2026US 12,560,614 B2Center for Immunology Science
- Methods and kits for diagnosing and/or treating peripheral neuropathy18 Mar 2025US 12,252,551 B2Academia Sinica
- Malate to detect and as a target for fibromyalgia4 Mar 2025US 12,241,889 B2University of Iowa Research Foundation
- Glycine receptors in white blood cells as biomarkers for pain24 Sep 2026US 2026/0287599 A1Texas Tech University System
- Method and reagents for the detection of an autoantibody13 Aug 2026US 2026/0235599 A1Centre National De La Recherche Scientifique
- Method to detect and treat peripheral neuropathy23 Jul 2026US 2026/0210976 A1Ohio State Innovation Foundation
- Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs29 Jan 2026US 2026/0028675 A1
- Monoclonal antibody against nerve growth factor, and encoding gene and use thereof10 Jul 2025US 2025/0223346 A1Akeso Biopharma, Inc.
Most cited
By later US patents
- Method and device for diagnosing and distinguishing chest pain in early onset thereof97US 5,747,274 ASpectral Diagnostics, Inc. · 1998
- Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-193US 7,598,228 B2Asubio Pharma Co., Ltd. · 2009
- Method and device for diagnosing and distinguishing chest pain in early onset thereof81US 5,604,105 ASpectral Diagnostics, Inc. · 1997
- Method and device for diagnosing and distinguishing chest pain in early onset thereof55US 5,710,008 ASpectral Diagnostics, Inc. · 1998
- Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors52US 8,106,167 B2Amgen Inc. · 2012